Seqalis joins the Oncode Accelerator Therapeutic Vaccines Workstream

Seqalis is proud to contribute its quantitative analytical expertise to the Oncode Accelerator Therapeutic Vaccines Workstream. Through its patented qTCR-Seq technology and collaborative approach, Seqalis helps strengthen the development of next-generation therapeutic cancer vaccines with robust, data-driven insights.

Read the full article to learn how this collaboration is supporting innovation in cancer immunotherapy.